The growing incidence in thyroid cancer results mainly from the detection of small or very small papillary thyroid carcinomas. The management of patients with such small tumors represents a major clinical challenge. Could evaluation of the BRAF status of such tumors aid risk stratification and patient management?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Basolo, F. et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 95, 4197–4205 (2010).
Soares, P. et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22, 4578–4580 (2003).
Rhoden, K. J. et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 91, 2414–2423 (2006).
Xing, M. et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977–2982 (2009).
Trovisco, V. et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 202, 247–251 (2004).
Castro, P., Fonseca, E., Magalhães, J. & Sobrinho-Simões, M. Follicular, papillary, and “hybrid” carcinomas of the thyroid. Endocr. Pathol. 13, 313–320 (2002).
Trovisco, V. et al. Type and prevalence of BRAF mutations are closely associated to papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 446, 589–595 (2005).
Castro, P. et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 213–220 (2006).
Ugolini, C. et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17, 381–388 (2007).
Xing, M. BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann. Surg. Oncol. 16, 801–803 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Soares, P., Sobrinho-Simões, M. Small papillary thyroid cancers—is BRAF of prognostic value?. Nat Rev Endocrinol 7, 9–10 (2011). https://doi.org/10.1038/nrendo.2010.213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.213
This article is cited by
-
Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
Endocrine Pathology (2021)
-
BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study
Modern Pathology (2015)
-
Prognostic biomarkers in thyroid cancer
Virchows Archiv (2014)
-
Molecular genetics and diagnosis of thyroid cancer
Nature Reviews Endocrinology (2011)
-
The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases
Virchows Archiv (2011)
